2)"Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies"
Current treatment strategies for COVID-19 can be classified into "target virus" and "target host" categories. Repurposing existing drugs, emerging drugs .. nature.com/articles/s4139โฆ
3) ...and promising potential targets fall under these categories.
For the host, ACE2 receptor, TMPRSS2 protease, inflammatory cytokines and their pathways, CD147, and HMGB1 are potential therapeutic targets based on their roles in viral entry/pathogenesis/excessive inflammation.
4) Future directions include focusing on more promising targets, strengthening multi-disciplinary cooperation, addressing gaps between preclinical/clinical research, and monitoring viral mutations. A combination of antiviral and immunomodulatory therapies may be most effective.
7) Potential therapeutic targets include viral proteins like spike, protease, RNA polymerase, and host proteins involved in viral entry/ immunopathology. Various agents have shown anti-SARS-CoV-2 activity in preclinical/clinical studies, but most require further development.
8) Treatment strategies aim to administer antiviral drugs early to outpatients, while immunomodulators may benefit severely ill inpatients. Treating long COVID remains challenging due to its unclear mechanisms. Development of pan-coronavirus therapies is another priority area.
9) Overall, while progress has been made, more convenient and broadly effective antiviral therapies are still needed to effectively tackle COVID-19 and future coronavirus outbreaks, including those targeting key viral proteins and able to counter emerging variants.
10) Thanks for reading ๐ and have a wonderful sunday ๐ค
โข โข โข
Missing some Tweet in this thread? You can try to
force a refresh
2) This study describes the emergence of the SARS-CoV-2 Omicron subvariant JN.1 in Tamil Nadu, India between November and December 2023. JN.1 rapidly replaced the previously dominant XBB variant.
3) 66 JN.1 positive samples underwent whole genome sequencing. The majority of patients were middle-aged, with equal male/female representation. Over 50% had diabetes and 21% had hypertension
2) The study analyzed data from household surveys and serological testing of over 5,800 individuals from 2,514 households in Utah from January to April 2021.
Around 12.8% of individuals showed serological evidence of prior SARS-CoV-2 infection, and 17.4% of households ...
3) ...had at least one positive individual.
A mathematical model was developed to estimate household transmission dynamics while accounting for variability, age/size heterogeneity, and test accuracy.
2) The paper analyzes aggregated foot traffic data from mobile devices to measure mobility and contact patterns across different place categories (restaurants, retail, etc.) in New York City neighborhoods during the COVID-19 pandemic in 2020.
3) It finds distinct mobility networks and indoor contact patterns (crowdedness, dwell time) vary across place categories and neighborhoods, driven by the local distribution of points of interest and human activities.
2) SARS-CoV-2 has undergone two major evolutionary jumps - from pre-Omicron variants to Omicron BA.1, and from XBB variants to BA.2.86/JN.1. These resulted in increased genetic divergence.
3) Variants like BA.1, XBB.1.5, BQ.1.1, and JN.1 displayed high relative growth advantages (116%, 80%, 71%, 93% respectively) allowing them to outcompete other co-circulating variants.
2) The study investigated the persistence of SARS-CoV-2 in tissues of patients who had recovered from mild COVID-19. Samples were collected from various tissues at 1 month, 2 months, and 4 months post-infection.
3) Viral RNA was detected in tissues like the liver, kidney, stomach, intestine, brain, blood vessels, lung, breast, skin, and thyroid across the timepoints, with detection rates gradually decreasing over time.
2) The study aimed to understand how repeated vaccination with the ancestral SARS-CoV-2 mRNA vaccine induces antibodies that can neutralize Omicron variants, which have mutations that allow immune escape.
3) They analyzed blood samples from 41 individuals who received three doses of the BNT162b2 mRNA vaccine. Samples were collected at various time points to track the immune response.